At the time of writing, Spyre Therapeutics Inc [SYRE] stock is trading at $13.96, up 2.87%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The SYRE shares have gain 7.22% over the last week, with a monthly amount drifted -23.17%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Spyre Therapeutics Inc [NASDAQ: SYRE] stock has seen the most recent analyst activity on April 08, 2025, when Leerink Partners initiated its Outperform rating and assigned the stock a price target of $45. Previously, Wolfe Research started tracking the stock with Outperform rating on March 18, 2025, and set its price target to $27. On September 04, 2024, Wedbush initiated with a Outperform rating and assigned a price target of $45 on the stock. Evercore ISI started tracking the stock assigning a Outperform rating. Robert W. Baird initiated its recommendation with a Outperform and recommended $50 as its price target on May 02, 2024. Wells Fargo upgraded its rating to Overweight for this stock on March 01, 2024, and upped its price target to $35. In a note dated December 20, 2023, BTIG Research initiated an Buy rating and provided a target price of $32 on this stock.
For the past year, the stock price of Spyre Therapeutics Inc fluctuated between $10.91 and $40.49. Currently, Wall Street analysts expect the stock to reach $71 within the next 12 months. Spyre Therapeutics Inc [NASDAQ: SYRE] shares were valued at $13.96 at the most recent close of the market. An investor can expect a potential return of 408.6% based on the average SYRE price forecast.
Analyzing the SYRE fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -0.61 and Total Capital is -0.38.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.33 points at the first support level, and at 12.71 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.31, and for the 2nd resistance point, it is at 14.67.
Ratios To Look Out For
It is important to note that Spyre Therapeutics Inc [NASDAQ:SYRE] has a current ratio of 11.26. Also, the Quick Ratio is 11.26, while the Cash Ratio stands at 1.65.
Transactions by insiders
Recent insider trading involved Albers Jeffrey W., Director, that happened on Nov 06 ’24 when 6700.0 shares were sold. Director, Albers Jeffrey W. completed a deal on Oct 25 ’24 to sell 300.0 shares. Meanwhile, Director SESSIONS, LLC bought 7000.0 shares on Oct 25 ’24.
